Regenerex Pharma (Regenerex Pharma) Change In Working Capital : $0.29 Mil (TTM As of Dec. 2023)

View and export this data going back to . Start your Free Trial

What is Regenerex Pharma Change In Working Capital?

Regenerex Pharma's change in working capital for the quarter that ended in Dec. 2023 was $0.12 Mil.

Regenerex Pharma's change in working capital for the fiscal year that ended in Mar. 2023 was $0.08 Mil.

It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement. Not by calculating the number changes in each periods' working capital (Total Current Assets minus Total Current Liabilities).

Regenerex Pharma Change In Working Capital Historical Data

The historical data trend for Regenerex Pharma's Change In Working Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Regenerex Pharma Change In Working Capital Chart

Regenerex Pharma Annual Data

Trend

Nov09

Nov10

Nov11

Nov12

Nov13

Nov14

Mar17

Mar18

Mar22

Mar23

Change In Working Capital

Get a 7-Day Free Trial

0.39

0.07

0.08

Regenerex Pharma Quarterly Data
	May14	Aug14	Nov14	Sep16	Dec16	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Change In Working Capital	Get a 7-Day Free Trial															0.02	0.04	0.02	0.11	0.12

Regenerex Pharma Change In Working Capital Calculation

Change In Working Capital for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.29 Mil.

Working Capital is a measure of a company's short term liquidity or its ability to cover short term liabilities. It is defined as the difference between a company's current assets and current liabilities.

Changes in Working Capital is reported in the cash flow statement since it is one of the major ways in which net income can differ from operating cash flow. It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement.

Use Wal-Mart Stores Inc (Jan 2014, Annual Data) as an example: Source: Wal-Mart Stores Inc 2014-01-31 10-K from SEC

Consolidated Statements of Cash Flows	Fiscal Years Ended	January 31,	(Amounts in millions)
Cash flows from operating activities:	2014	2013	2012
Changes in certain assets and liabilities, net of effects of acquisitions:
Receivables, net	(566)	(614)	(796)
Inventories	(1,667)	(2,759)	(3,727)
Accounts payable	531	1,061	2,687
Accrued liabilities	103	271	(935)
Accrued income taxes	(1,224)	981	994

For 2014-01-31, add all the items under 2014 collum together, Change in Working Capital was (566) + (1,667) + 531 + 103 + (1,224) = $ (2,823) Mil.

Regenerex Pharma Change In Working Capital Related Terms

Thank you for viewing the detailed overview of Regenerex Pharma's Change In Working Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

Regenerex Pharma (Regenerex Pharma) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Regenerex Pharma Inc (OTCPK:PEPT) » Definitions » Change In Working Capital

Comparable Companies

Traded in Other Exchanges

N/A

Address

5348 Vegas Drive, Suite 177, Las Vegas, NV, USA, 89108

Website

https://regenerexpharmainc.com

Regenerex Pharma Inc develops and markets Woundcare Healing products. The current product technology provides the Company with a number of complete wound care protocols to treat all wounds, such as diabetic ulcers, pressure ulcers, burns, and surgical wounds. Its product Xcellderma OTC a Liquid Bandage Skin Protectant Xcellderma products are sterile wound dressings for treating diabetic foot ulcers, pressure ulcers, and other chronic wounds; Accelerex Sterile Wound Cream is for the treatment of a wide variety of chronic and acute wounds; and Accelerex Impregnated Sterile Wound Dressing use as a wound dressing to manage pressure ulcers (stages I-IV), stasis ulcers, diabetic skin ulcers, skin irritations, cuts, and abrasions.

Regenerex Pharma (Regenerex Pharma) Headlines

No Headlines